TY - JOUR
T1 - Present and Future Therapeutic Approaches to Barrier Dysfunction
AU - Fortea, Marina
AU - Albert-Bayo, Mercé
AU - Abril-Gil, Mar
AU - Ganda Mall, John-Peter
AU - Serra-Ruiz, Xavier
AU - Henao-Paez, Alejandro
AU - Expósito, Elba
AU - González Castro, Ana Maria
AU - Guagnozzi, Danila
AU - Lobo Álvarez, Beatriz
AU - Alonso Cotoner, Carmen
AU - Santos, Javier
PY - 2021
Y1 - 2021
N2 - There is converging and increasing evidence, but also uncertainty, for the role of abnormal intestinal epithelial barrier function in the origin and development of a growing number of human gastrointestinal and extraintestinal inflammatory disorders, and their related complaints. Despite a vast literature addressing factors and mechanisms underlying changes in intestinal permeability in humans, and its connection to the appearance and severity of clinical symptoms, the ultimate link remains to be established in many cases. Accordingly, there are no directives or clinical guidelines related to the therapeutic management of intestinal permeability disorders that allow health professionals involved in the management of these patients to carry out a consensus treatment based on clinical evidence. Instead, there are multiple pseudoscientific approaches and commercial propaganda scattered on the internet that confuse those affected and health professionals and that often lack scientific rigor. Therefore, in this review we aim to shed light on the different therapeutic options, which include, among others, dietary management, nutraceuticals and medical devices, microbiota and drugs, and epigenetic and exosomes-manipulation, through an objective evaluation of the scientific publications in this field. Advances in the knowledge and management of intestinal permeability will sure enable better options of dealing with this group of common disorders to enhance quality of life of those affected.
AB - There is converging and increasing evidence, but also uncertainty, for the role of abnormal intestinal epithelial barrier function in the origin and development of a growing number of human gastrointestinal and extraintestinal inflammatory disorders, and their related complaints. Despite a vast literature addressing factors and mechanisms underlying changes in intestinal permeability in humans, and its connection to the appearance and severity of clinical symptoms, the ultimate link remains to be established in many cases. Accordingly, there are no directives or clinical guidelines related to the therapeutic management of intestinal permeability disorders that allow health professionals involved in the management of these patients to carry out a consensus treatment based on clinical evidence. Instead, there are multiple pseudoscientific approaches and commercial propaganda scattered on the internet that confuse those affected and health professionals and that often lack scientific rigor. Therefore, in this review we aim to shed light on the different therapeutic options, which include, among others, dietary management, nutraceuticals and medical devices, microbiota and drugs, and epigenetic and exosomes-manipulation, through an objective evaluation of the scientific publications in this field. Advances in the knowledge and management of intestinal permeability will sure enable better options of dealing with this group of common disorders to enhance quality of life of those affected.
KW - Epithelial barrier function
KW - Intestinal permeability
KW - Mast cell stabilizers
KW - Mucoprotectants
KW - Nutrients
KW - Prebiotics
KW - Probiotics
KW - Short chain fatty acids
U2 - 10.3389/fnut.2021.718093
DO - 10.3389/fnut.2021.718093
M3 - Article
C2 - 34778332
SN - 2296-861X
VL - 8
JO - Frontiers in Nutrition
JF - Frontiers in Nutrition
ER -